Vnitr Lek 2026, 72(2):104-112 | DOI: 10.36290/vnl.2026.022

New generation anti-obesity drugs and bone health in postmenopausal women

Jana Tomasová Studýnková

Revmatologický ústav Praha a Revmatologická klinika 1. LF UK, Praha

Obesity represents a major global medical and socioeconomic challenge. The prevalence of overweight and obesity has increased markedly over the past three decades and currently affects nearly one third of the world's population. Up to 70 % of women experience weight gain during the menopausal transition. Glucagon-like peptide-1 receptor agonists (GLP-1RA) represent an effective pharmacological treatment for overweight and obesity and have become an important therapeutic option across various populations, including peri- and postmenopausal women. Available data suggest that some of these agents may have a beneficial effect on bone mineral density and fracture risk; however, the number of studies specifically addressing this issue remains limited. The aim of this review is to summarize current evidence on the use of GLP-1 receptor agonists in peri- and postmenopausal women and to evaluate their potential effects on bone tissue and bone metabolism.

Keywords: obesity, GLP-1 receptor agonists, bone metabolism, postmenopausal osteoporosis, weight management, fracture risk, estrogen deficiency.

Accepted: March 25, 2026; Published: April 8, 2026  Show citation